Nina Bhardwaj

Jan 19, 2024 | nature.com | Matthew D. Galsky |Sudeh Izadmehr |Edgar Gonzalez-Kozlova |Kevin Chan |Christos E. Kyriakopoulos |Mahalya Gogerly-Moragoda | +5 more

Correction to: Nature Medicine https://doi.org/10.1038/s41591-023-02568-1, published online 2 October 2023. In the version of the article initially published, Diane M.

Oct 2, 2023 | nature.com | Matthew D. Galsky |Sudeh Izadmehr |Edgar Gonzalez-Kozlova |Kevin Chan |Christos E. Kyriakopoulos |Robert M. Samstein | +5 more

AbstractCystectomy is a standard treatment for muscle-invasive bladder cancer (MIBC), but it is life-altering. We initiated a phase 2 study in which patients with MIBC received four cycles of gemcitabine, cisplatin, plus nivolumab followed by clinical restaging. Patients achieving a clinical complete response (cCR) could proceed without cystectomy.

Sep 6, 2023 | cell.com | Sujit Nair |Dimple Chakravarty |Vaibhav Patel |Nina Bhardwaj

Neoadjuvant trials for GU cancers have a bright future, but there are still many unanswered questions (see Outstanding questions) that need to be addressed. Neoadjuvant trials allow for a quicker evaluation of the efficacy of drugs, and multiple studies investigating the role of novel agents or therapeutic combinations are currently being conducted (Figure 1, Key figure).

Jun 13, 2023 | cell.com | Matthew Brown |Michelle Tran |Nina Bhardwaj

Cookie Preference CenterWe use cookies which are necessary to make our site work. We may also use additional cookies to analyse, improve and personalise our content and your digital experience. For more information, see our Cookie Policy and the list of Google Ad-Tech Vendors. You may choose not to allow some types of cookies. However, blocking some types may impact your experience of our site and the services we are able to offer.